2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial

L. Bartolomei, M. Malaguti, A. Pastore, G.M. Minicuci, N. Bonetto, S. Ferrari, M. Pellegrini (Vicenza, Italy)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Effects of pyridostigmine bromide vs. fludrocortison in the treatment of orthostatic hypotension in Parkinson’s disease

S.R. Schreglmann, F. Büchele, M. Sommerauer, L. Epprecht, G. Kägi, S. Hägele-Link, O. Götze, L. Zimmerli, D. Waldvogel, C.R. Baumann (London, United Kingdom)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraphTM

I. Suttrup, V. Zentsch, J. Schroeder, T. Warnecke (Muenster, Germany)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Effects of the biodex stability system training on balance, gait and fatigue in Parkinson’s disease

G. Singh, R. Pahwa, K.E. Lyons, Y. Colgrove, N.K. Sharma (Troy, NY, USA)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Effects of videogame step training on gait adaptability in people with Parkinson´s disease – A randomized controlled trial

M.J.D. Caetano, J.C. Menant, C.G. Canning, J. Song, D. Schoene, M. Brodie, S.R. Lord (Sydney, Australia)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Efficacy and safety of abobotulinumtoxinA in craniocervical dystonia and hemifacial spasm

A. Jesic, D. Stefanovic, N. Delibasic, J. Radanov, M. Cvijanovic (Victoria, Seychelles)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Efficacy and safety of tetrabenazine in hyperkinetic movements disorders- An observational study

R. Miguel, M. Mendonça, R. Barbosa, F. Ladeira, T. Lampreia, J. Vale, P. Bugalho (Lisbon, Portugal)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Efficacy of 4845 botulinum toxin (BoNT) treatment cycles, and clinical strategies after a failed cycle

P. Tanvijit, A.P. Moore (Bangkok, Thailand)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2